The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis

Introduction The risk of oesophageal adenocarcinoma (OAC) in non-dysplastic Barrett's oesophagus (BO) may have been overestimated. The objective was to estimate the incidence of OAC in patients with BO without dysplasia. Methods The authors searched MEDLINE and EMBASE from 1966 to 2011 and performed a bibliographic review of previous publications, excluding abstracts, non-peer-reviewed publications and those not published in English, for prospective or retrospective studies of the incidence of OAC in patients with BO. They excluded patients with any degree of dysplasia at baseline and those without documented intestinal metaplasia. Studies were independently reviewed by two individuals. 57 of 3450 studies were included. The authors extracted information on number of patients with BO, length of follow-up, incident cases of OAC, mean age of patients, country of origin, whether prospective or retrospective, mean length of BO segments and mortality from causes other than OAC. Study quality was assessed by the Ottawa Newcastle criteria. Results The 57 included studies comprised 11 434 patients and 58 547 patient-years of follow-up. The pooled annual incidence of OAC was 0.33% (95% CI 0.28% to 0.38%). Among 16 studies that provided appropriate information on mortality, there were 56 incident cases of OAC but 684 deaths from apparently unrelated causes. Among 16 studies that provided information on patients with short-segment BO, the annual incidence of OAC was only 0.19%. Conclusions The incidence of OAC in non-dysplastic BO is around 1 per 300 patients per year. The incidence of OAC in short-segment BO is under 1 per 500 patients per year.

[1]  P. A. van den Brandt,et al.  Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  A. Zinsmeister,et al.  Epidemiology and Natural History of Intestinal Metaplasia of the Gastroesophageal Junction and Barrett's Esophagus: A Population-Based Study , 2011, The American Journal of Gastroenterology.

[3]  A. Gavin,et al.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. , 2011, Journal of the National Cancer Institute.

[4]  Prateek Sharma,et al.  American Gastroenterological Association technical review on the management of Barrett's esophagus. , 2011, Gastroenterology.

[5]  Amy Wang,et al.  Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  P. Sedgwick Meta-analyses III , 2011, BMJ : British Medical Journal.

[7]  C. Jackson,et al.  Surveillance in Barrett’s Esophagus: An Audit of Practice , 2010, Digestive Diseases and Sciences.

[8]  A. Nagar,et al.  Barrett's surveillance identifies patients with early esophageal adenocarcinoma. , 2010, The American journal of medicine.

[9]  D. Alderson,et al.  Long-term survival and cost analysis of an annual Barrett's surveillance programme , 2010, European journal of gastroenterology & hepatology.

[10]  E. Kuipers,et al.  Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  A. Bhattacharyya,et al.  Medication usage and the risk of neoplasia in patients with Barrett's esophagus. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  L. Lundell,et al.  Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  P. Bampton,et al.  Outcome of endoscopy surveillance for Barrett's oesophagus , 2009, ANZ journal of surgery.

[14]  A. Csendes,et al.  Late results of the surgical treatment of 125 patients with short-segment Barrett esophagus. , 2009, Archives of surgery.

[15]  A. Charlett,et al.  Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. , 2009, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[16]  A. Rastogi,et al.  Esophageal Adenocarcinoma in Barrett's Esophagus After Endoscopic Ablative Therapy: A Meta-Analysis and Systematic Review , 2009, The American Journal of Gastroenterology.

[17]  M. Vieth,et al.  Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. , 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[18]  Vicki Livingstone,et al.  Barrett's esophagus: A retrospective analysis of 13 years surveillance , 2008, Journal of Gastroenterology and Hepatology.

[19]  V. Lánská,et al.  Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett’s esophagus: a prospective cohort study , 2008, Endoscopy.

[20]  L. Murray,et al.  The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[21]  J. Going,et al.  Systematic Four-Quadrant Biopsy Detects Barrett's Dysplasia in More Patients Than Nonsystematic Biopsy , 2008, The American Journal of Gastroenterology.

[22]  R. Greenlee,et al.  Barrett's Esophagus: Incidence and Prevalence Estimates in a Rural Mid-Western Population , 2008, The American Journal of Gastroenterology.

[23]  P. Moayyedi,et al.  Mortality rates in patients with Barrett’s oesophagus , 2007, Alimentary pharmacology & therapeutics.

[24]  B. Shadbolt,et al.  Effect of proton pump inhibitors on markers of risk for high‐grade dysplasia and oesophageal cancer in Barrett’s oesophagus , 2007, Alimentary pharmacology & therapeutics.

[25]  D. Forman,et al.  Risk of Mortality and Cancer Incidence in Barrett's Esophagus , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  D. Treanor,et al.  Low-grade dysplasia in Barrett's esophagus has a high risk of progression , 2007, Endoscopy.

[27]  C. Lim1,et al.  Low-grade dysplasia in Barrett's esophagus has a high risk of progression , 2007 .

[28]  A. Mcintyre,et al.  A surveillance programme for Barrett's oesophagus in a UK general hospital , 2007, European journal of gastroenterology & hepatology.

[29]  T. Stephenson,et al.  Barrett's oesophagus: Intestinal metaplasia is not essential for cancer risk , 2007, Scandinavian journal of gastroenterology.

[30]  M Vieth,et al.  Frequency of Barrett’s neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study , 2006, Endoscopy.

[31]  R. Sampliner,et al.  Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  B. Cooper,et al.  Barrett's oesophagus: an audit of surveillance over a 17-year period , 2006, European journal of gastroenterology & hepatology.

[33]  B. Cooper,et al.  Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence , 2006, Alimentary pharmacology & therapeutics.

[34]  M. Rugge,et al.  Barrett’s epithelium after antireflux surgery , 2005, Journal of Gastrointestinal Surgery.

[35]  W. Dickey,et al.  Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland , 2005, European journal of gastroenterology & hepatology.

[36]  C. Nwokolo,et al.  Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival , 2005, European journal of gastroenterology & hepatology.

[37]  R. Willén,et al.  Barrett Esophagus: Risk Factors for Progression to Dysplasia and Adenocarcinoma , 2005, Annals of surgery.

[38]  P. Shekelle,et al.  Dysplasia and Risk of Further Neoplastic Progression in a Regional Veterans Administration Barrett's Cohort , 2005, The American Journal of Gastroenterology.

[39]  H. Höfler,et al.  The Munich Barrett follow up study: suspicion of Barrett’s oesophagus based on either endoscopy or histology only—what is the clinical significance? , 2004, Gut.

[40]  M. Solaymani-Dodaran,et al.  Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux , 2004, Gut.

[41]  J. Reynolds,et al.  Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. , 2004, American journal of surgery.

[42]  A. Csendes,et al.  Adenocarcinoma Appearing very late after antireflux surgery for barrett’s esophagus: long-term follow-up, review of the literature, and addition of six patients , 2004, Journal of Gastrointestinal Surgery.

[43]  P. Pairolero,et al.  Barrett's esophagus: the role of laparoscopic fundoplication. , 2004, The Annals of thoracic surgery.

[44]  J. de Caestecker,et al.  Audit of a Barrett's epithelium surveillance database , 2004, European journal of gastroenterology & hepatology.

[45]  E. Kuipers,et al.  Oesophageal cancer incidence and mortality in patients with long-segment Barrett's Oesophagus after a mean follow-up of 12.7 years , 2004, Scandinavian journal of gastroenterology.

[46]  N. Soper,et al.  Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. , 2003, American journal of surgery.

[47]  D. Oleynikov,et al.  Clinical and Pathologic Response of Barrett's Esophagus to Laparoscopic Antireflux Surgery , 2003, Annals of surgery.

[48]  J. Borovička,et al.  Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. , 2003, Swiss medical weekly.

[49]  A. Gavin,et al.  Risk of adenocarcinoma in Barrett's oesophagus: population based study , 2003, BMJ : British Medical Journal.

[50]  R. Cestari,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.

[51]  J. Peters,et al.  Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. , 2003, Journal of the American College of Surgeons.

[52]  F. Lewis Should we limit resident work hours? , 2003, Annals of surgery.

[53]  P. Parrilla,et al.  Long-Term Results of a Randomized Prospective Study Comparing Medical and Surgical Treatment of Barrett’s Esophagus , 2003, Annals of surgery.

[54]  J. Hunter,et al.  Clinical and histologic follow-up after antireflux surgery for Barrett’s esophagus , 2002, Journal of Gastrointestinal Surgery.

[55]  R. Fitzgerald,et al.  Rigorous Surveillance Protocol Increases Detection of Curable Cancers Associated with Barrett's Esophagus , 2001, Digestive Diseases and Sciences.

[56]  L. Gaboury,et al.  Proliferative Activity in Barrett’s Esophagus Before and After Antireflux Surgery , 2001, Annals of surgery.

[57]  V. Eckardt,et al.  Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. , 2001, The American journal of medicine.

[58]  R. Sampliner,et al.  Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. , 2001, JAMA.

[59]  D. Katzka,et al.  Maximal acid reflux control for Barrett’s oesophagus: feasible and effective , 2001, Alimentary pharmacology & therapeutics.

[60]  L. Melton,et al.  Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota , 2001, Gut.

[61]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[62]  D. Bowrey,et al.  Barrett's esophagus: a surgical disease? , 2000, The American journal of gastroenterology.

[63]  S. Spechler Barrett's esophagus: an overrated cancer risk factor. , 2000, Gastroenterology.

[64]  I. Wiklund,et al.  Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. , 2000, European journal of gastroenterology & hepatology.

[65]  R. Sandler,et al.  Is there publication bias in the reporting of cancer risk in Barrett's esophagus? , 2000, Gastroenterology.

[66]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[67]  Patricia L. Blount,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. , 2000 .

[68]  A. Axon,et al.  Barrett's oesophagus: results from a 13‐year surveillance programme , 2000, European journal of gastroenterology & hepatology.

[69]  B. Reid,et al.  Effect of Segment Length on Risk for Neoplastic Progression in Patients with Barrett Esophagus , 2000, Annals of Internal Medicine.

[70]  J. Dent,et al.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.

[71]  P. S. Rana,et al.  Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[72]  M. Mayo,et al.  Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia , 2000, Gut.

[73]  E. Kuipers,et al.  Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study , 1999, Gut.

[74]  Wilkinson,et al.  Regression of columnar‐lined (Barrett’s) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy , 1999, Alimentary pharmacology & therapeutics.

[75]  G. Falk,et al.  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999, American Journal of Gastroenterology.

[76]  P. Aló,et al.  DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. , 1998, Cytometry.

[77]  M. Luostarinen,et al.  Histological improvement of oesophagitis after Nissen fundoplication. , 1998, Annals of medicine.

[78]  Kenneth K Wang,et al.  Updated Guidelines 2008 for the Diagnosis, Surveillance and Therapy of Barrett's Esophagus , 1998, The American Journal of Gastroenterology.

[79]  P. Schoenfeld,et al.  Effectiveness and patient satisfaction with nurse-directed treatment of barrett's esophagus , 1998, American Journal of Gastroenterology.

[80]  F. Ellis,et al.  Endoscopic surveillance of barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer , 1998, American Journal of Gastroenterology.

[81]  A. Schned,et al.  The Development of Dysplasia and Adenocarcinoma During Endoscopic Surveillance of Barrett's Esophagus , 1998, American Journal of Gastroenterology.

[82]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[83]  G. Lapertosa,et al.  Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme , 1997, European journal of gastroenterology & hepatology.

[84]  M. Younes,et al.  p53 Protein Accumulation Is a Specific Marker of Malignant Potential in Barrett's Metaplasia , 1997, Digestive Diseases and Sciences.

[85]  R. Cherian,et al.  Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. , 1997, The American journal of gastroenterology.

[86]  S. Re,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997 .

[87]  G. Lapertosa,et al.  Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. , 1996, Gastrointestinal endoscopy.

[88]  W. Hogan,et al.  Barrett's ulcer: the clinical significance today. , 1996, The American journal of gastroenterology.

[89]  H. Smart,et al.  Cost effectiveness of detecting Barrett's cancer. , 1996, Gut.

[90]  P. Pairolero,et al.  Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? , 1996, The Journal of thoracic and cardiovascular surgery.

[91]  G. Morales,et al.  Conservative treatment versus antireflux surgery in Barrett's oesophagus: Long‐term results of a prospective study , 1996, The British journal of surgery.

[92]  W. Hop,et al.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.

[93]  C. Stoddard,et al.  Regression and progression of Barrett's oesophagus after antireflux surgery , 1995, The British journal of surgery.

[94]  R. Goyal,et al.  Prevalence of metaplasia at the gastro-oesophageal junction , 1994, The Lancet.

[95]  A. Barlow,et al.  Barrett's oesophagus: Effect of antireflux surgery on symptom control and development of complications , 1992, The British journal of surgery.

[96]  J. Hardcastle,et al.  Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. , 1992, Gut.

[97]  J. Jankowski Adenocarcinoma and Barrett's oesophagus. , 1992, Gut.

[98]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[99]  F. Ellis,et al.  Barrett's esophagus. Prevalence and incidence of adenocarcinoma. , 1991, Archives of internal medicine.

[100]  S. DeMeester,et al.  Surgical therapy for Barrett's esophagus. , 1990, Thoracic surgery clinics.

[101]  F. Ellis,et al.  Effect of antireflux operation on Barrett's mucosa. , 1990, The Annals of thoracic surgery.

[102]  E. Kivilaakso,et al.  Adenocarcinoma arising in Barrett's esophagus , 1989, Digestive Diseases and Sciences.

[103]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[104]  J. Mayberry,et al.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus , 1988, The British journal of surgery.

[105]  E. Achkar,et al.  The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. , 1988, The American journal of gastroenterology.

[106]  R C Heading,et al.  Barrett's oesophagus. , 1987, British medical journal.

[107]  W S Payne,et al.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. , 1985, The New England journal of medicine.

[108]  W G Doos,et al.  Adenocarcinoma and Barrett's esophagus. An overrated risk? , 1984, Gastroenterology.

[109]  Á. Lanas,et al.  Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. , 2009, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[110]  C. Wahlen,et al.  Laparoscopic treatment of Barrett’s esophagus: long-term results , 2005, Surgical Endoscopy.

[111]  D. Levine,et al.  Histological and anatomic changes in Barrett's esophagus after antireflux surgery , 1999, American Journal of Gastroenterology.

[112]  R. Sampliner,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997, The American journal of gastroenterology.

[113]  K. Moghissi,et al.  Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study. , 1993, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[114]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[115]  J. Sloan,et al.  The incidence of adenocarcinoma in Barrett's oesophagus and an evaluation of endoscopic surveillance , 1991 .

[116]  R. McCallum,et al.  Benign Lesions of the Esophagus and Cancer , 1989, Springer Berlin Heidelberg.

[117]  P. Monnier,et al.  Frequency and Importance of Endobrachyesophagus in Reflux Disease , 1988 .